Volagidemab

DB16421InvestigationalProtein Based Therapies

Volagidemab is under investigation in clinical trial NCT03117998 (Multiple Dose Study to Evaluate the Efficacy, Safety and Pharmacodynamics of REMD-477 in Subjects With Type 1 Diabetes Mellitus).

Mechanism: Pharmacologically active on Glucagon receptor
Curator reviewed
Code names: AMG-477 · REMD-477

Resolves to

Compound

UNII77JYS6UZ0MCAS1233956-13-2

Targets

P47871GCGR

What you can answer from here — as of June 15, 2026

1Protein targetEach mapped to UniProt, with action and pharmacological action

Listed above

381Drug interactionsStructured to mechanism, not free text

10Clinical trialsPhase, status and sponsor resolved per trial

3+ReferencesStructured and connected to the statements they support

Which drugs share a target with Volagidemab, and which of those have an active Phase 3 trial?

Answer this in Biopharma OS Sign in to your account

Create a free account or log in to explore the full data card.

Create Account